Myasthenia gravis trials in Greece

In Greece 7 Also abroad 123

7 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Athens, Chaïdári, Larissa, Patras
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Athens, Chaïdári, Larissa, Patras
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Athens, Thessaloniki
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Athens, Thessaloniki
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Larissa, Patras, Thessaloniki
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Athens, Thessaloniki
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Where
Athens, Chaïdári, Patras, Thessaloniki
Age
18 years to 80 years
People
231 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00